Study to Evaluate Long-term Effectiveness and Safety, Patient Characteristics and Subjective Patient-reported Outcomes of Dupilumab in Patients With Chronic Obstructive Pulmonary Disease (COPD) Under Real-world Conditions
← catalyst calendarNCT07052396 · readout in 1,046 d
Sponsored by Sanofi (industry) · SNY — their whole pipeline →. With Regeneron Pharmaceuticals.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
350estimated
Sites
18
Country
Germany
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-07-01 | actual | When the study began enrolling |
| Primary completion | 2029-07-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-07-01 | estimated | The whole study's end, after follow-up |
| First posted | 2025-07-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic Obstructive Pulmonary Disease (COPD)
Intervention
- Drug: Dupilumab
Primary outcome
what the primary-completion date above is the date OFChange from Baseline in COPD Assessment Test (CAT) Score
measured Baseline up to 12 months
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed